Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en hématologie en 2009
Bonnet, Christophe ULg; Beguin, Yves ULg; De Prijck, Bernard ULg et al

in Revue Médicale de Liège (2009), 64

Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and ... [more ▼]

Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and offers superior response and survival rates. 90Y ibritumomab tiuxetan (Zevalin) combines the specificity of rituximab for the CD20 antigen and the therapeutic effect of β irradiation. Given in monotherapy, it constitutes an interesting alternative therapy for follicular lymphomas in second relapse. Alemtuzumab (MabCampath) recognizes the CD52 antigen and offers encouraging results in chronic lymphocytic leukemia resistant to classical chemotherapy. [less ▲]

Detailed reference viewed: 265 (14 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en neurologie.
JEDIDI, Zayd ULg; Jedidi, Haroun ULg; Moonen, Gustave ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 305-9

Since their inception in the 1970's, monoclonal antibody therapies became increasingly efficient and common in numerous medical conditions and their use in neurology has been boosted during the last ... [more ▼]

Since their inception in the 1970's, monoclonal antibody therapies became increasingly efficient and common in numerous medical conditions and their use in neurology has been boosted during the last couple of years with the rise of natalizumab (Tysabri). Furthermore, if most monoclonal antibodies currently assessed in neurologic conditions remain considered as experimental, they may soon become first-line approved treatments in a broad range of neuromuscular and demyelinating diseases. Since the introduction of new therapies is likely to unravel specific adverse events and sui generis iatrogenic disorders, it is important to be able to recognize the side-effects of monoclonal antibodies delivered for neurological or non-neurological diseases. [less ▲]

Detailed reference viewed: 216 (22 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en thérapeutique.
Scheen, André ULg; Moutschen, Michel ULg

in Revue Médicale de Liège (2009), 64(5-6), 233-6

Detailed reference viewed: 97 (7 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en transplantation rénale
Bonvoisin, Catherine ULg; Weekers, Laurent ULg; Grosch, Stéphanie ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 287-292

Renal transplantation is the best treatment for end-stage renal disease, but requires efficient immunosuppressive therapy. The latter has evolved over recent years with the development of more powerful ... [more ▼]

Renal transplantation is the best treatment for end-stage renal disease, but requires efficient immunosuppressive therapy. The latter has evolved over recent years with the development of more powerful drugs and of monoclonal antibodies with very specific target. The first monoclonal antibodies, acting against the interleukin 2 receptor, named basiliximab and daclizumab, have showed an excellent tolerance profile and efficacy to reduce acute graft rejection. However, in spite of these properties, the development of delayed graft function or the graft and patient survivals at 1 year were not modified by the use of such specific treatment. One potential advantage could yet be a decreasing need for corticosteroids and sometimes calcineurin inhibitors which could provide some long term benefits for the renal graft, but also the patient. Alemtuzumab, another monoclonal antibody, aimed at the membrane glycoprotein CD52, can also decrease the incidence of acute rejection and the depth of the required immunosuppressive therapy. Other antibodies are still in development with some interesting preliminary results which however demand confirmation in larger studies. [less ▲]

Detailed reference viewed: 67 (1 ULg)
Full Text
Peer Reviewed
See detailANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques
Collignon, Joëlle ULg; Gennigens, Christine ULg; Rorive, Andrée ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 279-83

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of ... [more ▼]

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of targeted therapies in subgroups of cancers. One of the first validation of targeted therapy is the anti-HER-2 monoclonal antibody trastuzumab (Herceptin) in patients with overexpression of human epidermal growth factor receptor type 2 (HER2) occurring in 20 to 25% of invasive breast carcinoma. Trastuzumab binds the extracellular juxtamembrane domain and is only active in tumor with HER2 gene amplification detected by fluorescence in situ hybridization (FISH). The results from randomized trials have rapidly lead to the approvement of the drug in the metastatic and then in the adjuvant setting. Another targeted therapy, also approved in the treatment of breast cancer, is the monoclonal antibody bevacizumab with an anti-VEGF (Vascular Endothelial Growth Factor) activity. We will review the benefit of these targeted therapies in breast cancer and their role in the treatment of breast cancer. [less ▲]

Detailed reference viewed: 507 (43 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux
Thiry, Etienne ULg; Pastoret, Paul-Pierre ULg

in Annales de Médecine Vétérinaire (1981), 125

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailAnticyclonic eddies in the deep eastern Black Sea in summer-autumn 1999 (satellite and ship-borne observations
Ginzburg, Anna I.; Zatsepin, Andrey; Kostianoy, Andrey G. et al

in Earth Observation and Remote Sensing (2001), 5

Detailed reference viewed: 30 (7 ULg)
Full Text
Peer Reviewed
See detailAntidepressant medications and osteoporosis
Rizzoli, R; Cooper, C; Reginster, Jean-Yves ULg et al

in BONE (2012), 51

Detailed reference viewed: 30 (1 ULg)
See detailAntidepressant use and fracture risk: a meta-analysis
Bruyère, Olivier ULg

Conference (2012, March 24)

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailLes antidépresseurs dans la dépression majeure: La dose a-t-elle de l'importance?
PITCHOT, William ULg

in Acta Psychiatrica Belgica (2013)

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailLes antidépresseurs du futur : rôle du système glutamatergique.
PITCHOT, William ULg; Scantamburlo, Gabrielle ULg; Ansseau, Marc ULg

in Revue Médicale de Liège (2011), 66(4), 195-198

Detailed reference viewed: 29 (0 ULg)
See detailAntidépresseurs et risque fracturaire
Bruyère, Olivier ULg

Scientific conference (2012, February 24)

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailAntidépresseurs et syndrome d'interruption
PITCHOT, William ULg

in Acta Psychiatrica Belgica (2013)

Detailed reference viewed: 22 (1 ULg)
Full Text
See detailLes antidépresseurs
Ansseau, Marc ULg; PITCHOT, William ULg

in Rouillon, Fréderic (Ed.) Manuel de Psychiatrie (2012)

Detailed reference viewed: 27 (9 ULg)
Full Text
See detailLes antidépresseurs.
Ansseau, Marc ULg; Pitchot, William ULg

in Guelfi, J. D.; Rouillon, F. (Eds.) Manuel de Psychiatrie (2007)

Detailed reference viewed: 30 (3 ULg)
Full Text
Peer Reviewed
See detailAntidiabetic agents: Potential anti-inflammatory activity beyond glucose control.
Scheen, André ULg; ESSER, Nathalie ULg; Paquot, Nicolas ULg

in Diabetes & metabolism (2015)

A growing body of evidence is emerging to show that abdominal obesity, the metabolic syndrome, type 2 diabetes, cardiovascular disease and microvascular diabetic complications are intimately related to ... [more ▼]

A growing body of evidence is emerging to show that abdominal obesity, the metabolic syndrome, type 2 diabetes, cardiovascular disease and microvascular diabetic complications are intimately related to chronic inflammation. These observations pave the way to the development of new pharmacological strategies that aim to reduce silent inflammation. However, besides specific anti-inflammatory agents, glucose-lowering medications may also exert anti-inflammatory effects that could contribute to improved outcomes in diabetic patients. Most studies have used metformin, an AMP-activated protein kinase (AMPK) activator, and thiazolidinediones (TZDs), which act as peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists. Both pharmacological classes (considered insulin-sparing agents or insulin sensitizers) appear to have greater anti-inflammatory activity than insulin-secreting agents such as sulphonylureas or glinides. In particular, TZDs have shown the widest range of evidence of lowered tissue (visceral fat and liver) and serum inflammation. In contrast, despite reducing postprandial hyperglycaemia, the effect of alpha-glucosidase inhibitors on inflammatory markers appears rather modest, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) and glucagon-like peptide-1 (GLP-1) receptor agonists appear more promising in this respect. These incretin-based therapies exert pleiotropic effects, including reports of anti-inflammatory activity. No human data are available so far regarding sodium-glucose cotransporter type 2 (SGLT2) inhibitors. Although they may have indirect effects due to reduced glucotoxicity, their specific mode of action in the kidneys does not suggest systemic anti-inflammatory activity. Also, in spite of the complex relationship between insulin and atherosclerosis, exogenous insulin may also exert anti-inflammatory effects. Nevertheless, for all these glucose-lowering agents, it is essential to distinguish between anti-inflammatory effects resulting from better glucose control and potential anti-inflammatory effects related to intrinsic actions of the pharmacological class. Finally, it would also be of major clinical interest to define what role the anti-inflammatory effects of these glucose-lowering agents may play in the prevention of macrovascular and microvascular diabetic complications. [less ▲]

Detailed reference viewed: 42 (10 ULg)
Full Text
Peer Reviewed
See detailAntidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique
SCHEEN, André ULg

in Médecine des Maladies Métaboliques (2015), 9(2), 186-197

Oral therapy of type 2 diabetes (T2D) is becoming increasingly complex during the last decade, with first the launch of glitazones, then that of gliptins and finally, very recently, that of gliflozins ... [more ▼]

Oral therapy of type 2 diabetes (T2D) is becoming increasingly complex during the last decade, with first the launch of glitazones, then that of gliptins and finally, very recently, that of gliflozins. However, the two oral glucose-lowering agents developed more than 50 years ago, metformin and sulfonylureas, still remain the leaders in the market. After failure of metformin monotherapy, the choice of antidiabetic medications is difficult and should be made taking into account the benefit-risk balance, with a special attention to cost of therapy and a focus on a patient-centered approach. This strategy is recommended in the recently updated joint ADA-EASD position statement, in January 2015. If the main principles of T2D therapy are universal, particularities should probably be discussed regarding regional situations, and the African continent obviously presents specificities in this respect. [less ▲]

Detailed reference viewed: 81 (13 ULg)